Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


XenoPort accuses GSK of contract breach, failing to maximise sales of Horizant

This article was originally published in Scrip

Executive Summary

XenoPort said it has delivered a breach of contract notice to GlaxoSmithKline, its commercial partner, alleging GSK has not met its obligation to maximise the US sales of their product, Horizant (gabapentin encarbil) extended-release tablets for restless legs syndrome (RLS), according to a 25 January regulatory filing. GSK has 90 days to address the issues raised.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts